SOUTHFIELD, Mich., March 8, 2022 /PRNewswire-PRWeb/ -- Housey Pharma, a commercial stage biopharmaceutical company, (www.housey.com) announced today that Mr. Henry Hadad, Senior Vice President and Deputy General Counsel of Bristol Myers Squibb, has joined its Advisory Board. Mr. Hadad has extensive experience in the pharmaceutical industry and particular expertise in intellectual property matters. Housey Pharma's Advisory Board consists of medical specialists, clinical development experts, regulatory strategy advisors, experts in intellectual property matters and general business and legal advisors.
Mr. Hadad is currently Chief Intellectual Property Counsel as well as lead counsel to the Research & Early Development and Global Pharmaceutical Supply organizations at Bristol Myers Squibb, where he has been employed for more than a decade. He has previously worked for other major pharmaceutical companies including Johnson & Johnson and Schering Plough. He is a board member and was past president of the Intellectual Property Owner's Association (2018-2019). Mr. Hadad has lectured on IP issues around the world and has been a leading advocate for a stronger and more predictable global IP system, including testifying before Congress on this topic. Mr. Hadad earned his law degree from Washington College of Law at American University and his undergraduate degree in biology from Haverford College.
Gerard Housey, M.D., Ph.D., founder and CEO of Housey Pharma stated, "We are very pleased to have Henry Hadad join our Advisory Board. He is a world class intellectual property advisor who will add significant value to our Company as we continue to develop an extensive portfolio of US and international patents relating to novel drugs and drug targets as well as discovery methods for compounds that are effective against targets that were previously thought to be undruggable. We are excited to add an executive of Henry's caliber to our Advisory Board to help facilitate our continued growth."
Mr. Hadad said, "I am pleased to join the Advisory Board at Housey Pharma and to be associated with such an exceptional group of scientists and researchers. Housey Pharma has an exciting pipeline that has the potential to improve the lives of millions of patients. I look forward to seeing those technologies advanced in the years ahead."
Scientists at Housey Pharma have developed the next generation of drug-discovery technology in the cell-based assay field. The Company's technologies are being offered for licensure on a non-exclusive basis to other research-based pharmaceutical companies worldwide. Cell-based assay systems are research tools that use living cells to identify and refine new medicines.
The platform enables the creation of target-specific, cell-based assay systems through the use of technologies in genetic engineering, biochemistry and cell-biology. It is especially well-suited to targets previously thought to be "undruggable" in the human genome. "Undruggable" targets is a term used in the pharmaceutical industry to refer to biomolecules for which it was previously believed to be impossible to create a medicine capable of altering the biological function of the target in a therapeutically beneficial manner.
The licensed drug-discovery platform technology has been awarded 11 patents in the United States and dozens of other countries worldwide, with many more pending. The technology includes methods of discovering compounds that overcome drug-resistant cancers, generalized drug discovery and lead- optimization methods applicable to all human diseases, and certain compounds. The technology is particularly applicable to the discovery and development of protein kinase inhibitors useful for the treatment of drug-resistant cancers. Numerous major pharmaceutical companies have already licensed this technology from Housey Pharma
About Housey Pharma
Housey Pharma is a commercial stage, privately held biopharmaceutical company engaged in the discovery, research, development and sale of medicines that address important, unserved medical and health needs. Housey Pharma's products are created through the application of advanced, patented and proprietary drug discovery technologies invented by Housey Pharma. The Company believes its patented technologies comprise a core-enabling technology platform that provides it with a competitive advantage for new drug discovery and creation.
Housey Pharma has several therapeutic innovations under development within the field of diabetes and metabolism. The most advanced discovery is a first-in-class anti-diabetic medication that Housey Pharma plans to advance into Phase 2 clinical studies in 2022. This compound targets the Insulin Receptor Substrate-2 (IRS-2) pathway in human cells. IRS-2 is a protein previously considered to be an "undruggable" target. The mechanism of action of this compound is to overcome insulin resistance potentially leading to better control of blood glucose as well as reduced insulin levels. For more information, visit http://www.housey.com.
Jeff Caponigro, Housey Pharmaceutical Research Laboratories, LLC, 1 (248) 388-4981, [email protected]
SOURCE Housey Pharmaceutical Research Laboratories, LLC